Business News • PR NewsWire • Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections

Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections

Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections

CHAPEL HILL, North Carolina and NESS ZIONA, Israel, September 25, 2018 /PRNewswire/ -- Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced the independent Data Monitoring Committee (DMC) completed its pre-planned safety...

View More : https://www.prnewswire.com:443/news-releases/atox-bio-announces-independent-safety-monitoring-committee-recommendation-t...

Releted News by prnewswire

Global Maker and Innovator Community to Solve USD $1 Million Call for Action

CommerceWest Bank Partnered with WHW, Formerly Known as Women Helping Women

Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium

Holmusk Raises US$9.75 Million in Pre-Series A Financing